How we treat neurological toxicity from immune checkpoint inhibitors

Neurological adverse events from immune checkpoint inhibition are increasingly recognised, especially with combination anti-cytotoxic T-lymphocyte antigen 4 (CTLA4) and anti-programmed death receptor 1 (anti-PD-1) therapies. Their presenting symptoms and signs are often subacute and highly variable,...

Descripción completa

Detalles Bibliográficos
Autores principales: Spain, Lavinia, Tippu, Zayd, Larkin, James M, Carr, Aisling, Turajlic, Samra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6678012/
https://www.ncbi.nlm.nih.gov/pubmed/31423344
http://dx.doi.org/10.1136/esmoopen-2019-000540

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6678012/
https://www.ncbi.nlm.nih.gov/pubmed/31423344
http://dx.doi.org/10.1136/esmoopen-2019-000540

Ejemplares similares